APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Therapeutics

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Selected research

Market Outlook & Growth Opportunities

Global Peptide Therapeutics Market Outlook and Growth Opportunities 2026

25 December 2025193 pages

Choose your research edition.

Industry ResearchPeptide Therapeutics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Therapeutics Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Therapeutics Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.

Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%.

North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent.

Read the full market overview

In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.

This report provides an overview of the global Peptide Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide Therapeutics market.

Peptide Therapeutics Segment by Company

Sanofi

Teva

Novo Nordisk

Takeda

Eli Lilly

AstraZeneca

Novartis

AbbVie

Ipsen

Ferring

Merck

The Medicines

J & J

Peptide Therapeutics Segment by Type

Injection

Oral

Other

Peptide Therapeutics Segment by Application

Cancer

Metabolic Disorders

Central Nervous System

Other

Peptide Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Peptide Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Therapeutics industry.

Chapter 3: Detailed analysis of Peptide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Therapeutics Industry Trends Table 2. Peptide Therapeutics Industry Drivers Table 3. Peptide Therapeutics Industry Opportunities and Challenges Table 4. Peptide Therapeutics Industry Restraints Table 5. Global Peptide Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Peptide Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Peptide Therapeutics Company, Product Type & Application Table 10. Global Peptide Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Injection Table 15. Significant Companies of Oral Table 16. Significant Companies of Other Table 17. Global Peptide Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Peptide Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Peptide Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Peptide Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Peptide Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Cancer Table 23. Significant Companies of Metabolic Disorders Table 24. Significant Companies of Central Nervous System Table 25. Significant Companies of Other Table 26. Global Peptide Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptide Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Peptide Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Peptide Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Peptide Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Peptide Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptide Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Peptide Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Peptide Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Peptide Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Peptide Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peptide Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Peptide Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Peptide Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Peptide Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Sanofi Peptide Therapeutics Product Portfolio Table 45. Sanofi Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Peptide Therapeutics Product Portfolio Table 50. Teva Recent Development Table 51. Novo Nordisk Company Information Table 52. Novo Nordisk Business Overview Table 53. Novo Nordisk Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Novo Nordisk Peptide Therapeutics Product Portfolio Table 55. Novo Nordisk Recent Development Table 56. Takeda Company Information Table 57. Takeda Business Overview Table 58. Takeda Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Takeda Peptide Therapeutics Product Portfolio Table 60. Takeda Recent Development Table 61. Eli Lilly Company Information Table 62. Eli Lilly Business Overview Table 63. Eli Lilly Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Eli Lilly Peptide Therapeutics Product Portfolio Table 65. Eli Lilly Recent Development Table 66. AstraZeneca Company Information Table 67. AstraZeneca Business Overview Table 68. AstraZeneca Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AstraZeneca Peptide Therapeutics Product Portfolio Table 70. AstraZeneca Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis Peptide Therapeutics Product Portfolio Table 75. Novartis Recent Development Table 76. AbbVie Company Information Table 77. AbbVie Business Overview Table 78. AbbVie Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. AbbVie Peptide Therapeutics Product Portfolio Table 80. AbbVie Recent Development Table 81. Ipsen Company Information Table 82. Ipsen Business Overview Table 83. Ipsen Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ipsen Peptide Therapeutics Product Portfolio Table 85. Ipsen Recent Development Table 86. Ferring Company Information Table 87. Ferring Business Overview Table 88. Ferring Peptide Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Ferring Peptide Therapeutics Product Portfolio Table 90. Ferring Recent Development Table 91. Merck Company Information Table 92. Merck Business Overview Table 93. Merck Peptide Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Merck Peptide Therapeutics Product Portfolio Table 95. Merck Recent Development Table 96. The Medicines Company Information Table 97. The Medicines Business Overview Table 98. The Medicines Peptide Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. The Medicines Peptide Therapeutics Product Portfolio Table 100. The Medicines Recent Development Table 101. J & J Company Information Table 102. J & J Business Overview Table 103. J & J Peptide Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. J & J Peptide Therapeutics Product Portfolio Table 105. J & J Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Peptide Therapeutics Product Image Figure 2. Global Peptide Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Injection Image Figure 8. Oral Image Figure 9. Other Image Figure 10. Global Peptide Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Peptide Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Peptide Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Cancer Image Figure 14. Metabolic Disorders Image Figure 15. Central Nervous System Image Figure 16. Other Image Figure 17. Global Peptide Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peptide Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Peptide Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Peptide Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Peptide Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Peptide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Peptide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Peptide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Peptide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Peptide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Peptide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Peptide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Peptide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Peptide Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Peptide Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Peptide Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other
Companies covered
  • Sanofi
  • Teva
  • Novo Nordisk
  • Takeda
  • Eli Lilly
  • AstraZeneca
  • Novartis
  • AbbVie
  • Ipsen
  • Ferring
  • Merck
  • The Medicines
  • J & J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide Therapeutics Market Dynamics
  1. 2.1 Peptide Therapeutics Industry Trends
  2. 2.2 Peptide Therapeutics Industry Drivers
  3. 2.3 Peptide Therapeutics Industry Opportunities and Challenges
  4. 2.4 Peptide Therapeutics Industry Restraints
3 Peptide Therapeutics Market by Company
  1. 3.1 Global Peptide Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Peptide Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide Therapeutics Company Product Type and Application
  6. 3.6 Global Peptide Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide Therapeutics Market by Type
  1. 4.1 Peptide Therapeutics Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.1.3 Other
  5. 4.2 Global Peptide Therapeutics Sales Value by Type
  6. 4.2.1 Global Peptide Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Peptide Therapeutics Sales Value Share by Type (2021-2032)
5 Peptide Therapeutics Market by Application
  1. 5.1 Peptide Therapeutics Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Central Nervous System
  5. 5.1.4 Other
  6. 5.2 Global Peptide Therapeutics Sales Value by Application
  7. 5.2.1 Global Peptide Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Peptide Therapeutics Sales Value by Application (2021-2032)
  9. 5.2.3 Global Peptide Therapeutics Sales Value Share by Application (2021-2032)
6 Peptide Therapeutics Regional Value Analysis
  1. 6.1 Global Peptide Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Peptide Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Peptide Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Peptide Therapeutics Country-level Value Analysis
  1. 7.1 Global Peptide Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Peptide Therapeutics Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Peptide Therapeutics Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Peptide Therapeutics Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Takeda
  20. 8.4.1 Takeda Company Information
  21. 8.4.2 Takeda Business Overview
  22. 8.4.3 Takeda Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Takeda Peptide Therapeutics Product Portfolio
  24. 8.4.5 Takeda Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Peptide Therapeutics Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Peptide Therapeutics Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Peptide Therapeutics Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Peptide Therapeutics Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 Ipsen
  50. 8.9.1 Ipsen Company Information
  51. 8.9.2 Ipsen Business Overview
  52. 8.9.3 Ipsen Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ipsen Peptide Therapeutics Product Portfolio
  54. 8.9.5 Ipsen Recent Developments
  55. 8.10 Ferring
  56. 8.10.1 Ferring Company Information
  57. 8.10.2 Ferring Business Overview
  58. 8.10.3 Ferring Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ferring Peptide Therapeutics Product Portfolio
  60. 8.10.5 Ferring Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck Peptide Therapeutics Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 The Medicines
  68. 8.12.1 The Medicines Company Information
  69. 8.12.2 The Medicines Business Overview
  70. 8.12.3 The Medicines Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 The Medicines Peptide Therapeutics Product Portfolio
  72. 8.12.5 The Medicines Recent Developments
  73. 8.13 J & J
  74. 8.13.1 J & J Company Information
  75. 8.13.2 J & J Business Overview
  76. 8.13.3 J & J Peptide Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 J & J Peptide Therapeutics Product Portfolio
  78. 8.13.5 J & J Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst